Panobinostat combination demonstrates benefit in relapsed/refractory multiple myeloma
the ONA take:
According to results presented at the 20th Congress of the European Hematology Association, researchers have found that patients with relapsed or refractory myeloma experience the most benefit from panobinostat plus bortezomib and dexamethasone if they have received at least two prior treatment regimens, including an immunomodulatory agent and bortezomib.
The subgroup analysis, which included 147 patients, demonstrated a 12.5-month progression-free survival for patients who had received at least 2 prior regimens and received panobinostat compared with a progression-free survival of 4.7 months with placebo.
The overall study showed a 3.9-month improvement in median progression-free survival with panobinostat versus placebo.
"Together, these data identify the subgroup of patients with relapsed or relapsed and refractory [multiple myeloma] who benefits most with panobinostat-bortezomib-dexamethasone," Dr. Hermann Einsele, director of the Medical Clinic at University of Wurzberg in Germany said. "The findings support the recent [Food and Drug Administration] approval of the panobinostat combination in [multiple myeloma] patients who received ≥2 prior regimens, including IMiDs and bortezomib."
Patients with relapsed or refractory myeloma experience the most benefit from panobinostat plus bortezomib and dexamethasone.
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|